Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax or Gilteritinib with Intensive Chemotherapy in Young Newly Diagnosed AML
NCT06652685Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
- Sponsor
- Ruijin Hospital
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Conditions
- acute myeloid leukemia (AML)
01
Overview
Phase 2, open-label trial of venetoclax and gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Composite Complete Remission Rate. Planned start Oct 2024; status: not yet recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
D5-PBCR(-) IA arm
Standard IA induction for early responders
D5-PBCR(+) IA+Venetoclax arm
IA + Venetoclax for early non-responders
03
Who it enrols
Young patients (18-59) with newly diagnosed AML (excluding APL and CBF-AML) and adequate organ function.
04
Endpoints
Primary
Composite Complete Remission Rate
Secondary
Total Composite Complete Remission Rate
Overall Survival
Event-Free Survival
Adverse Events
Recovery Time for Neutrophils and Platelets
Beyond the preview
Go deeper on NCT06652685.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652685.